Compare YORW & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YORW | ADCT |
|---|---|---|
| Founded | 1816 | 2011 |
| Country | United States | Switzerland |
| Employees | 104 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.0M | 484.4M |
| IPO Year | 1994 | 2019 |
| Metric | YORW | ADCT |
|---|---|---|
| Price | $31.05 | $4.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 71.8K | ★ 875.6K |
| Earning Date | 06-08-2026 | 05-25-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ 1.39 | N/A |
| Revenue | $77,488,000.00 | ★ $81,357,000.00 |
| Revenue This Year | $14.53 | $1.15 |
| Revenue Next Year | $5.77 | $86.93 |
| P/E Ratio | $22.35 | ★ N/A |
| Revenue Growth | 3.37 | ★ 14.85 |
| 52 Week Low | $29.68 | $1.05 |
| 52 Week High | $36.48 | $4.98 |
| Indicator | YORW | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 31.75 | 69.79 |
| Support Level | $30.02 | $3.25 |
| Resistance Level | $32.98 | N/A |
| Average True Range (ATR) | 0.64 | 0.27 |
| MACD | -0.19 | 0.05 |
| Stochastic Oscillator | 6.60 | 90.38 |
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).